Retail French - June 10 W.indd

Prix | Nouveaux produits Changements aux formulaires
Nouveaux DIN | Emballages | Nouvelles des sociétés
Aux pharmaciens
LE BABILLARD
Un service de Health Response Limited
Mercredi, 10 juin 2009
Tarification dans le cadre du
programme du RCDP
Comme vous le savez, GlaxoSmithKline est un partenaire
stratégique du RCDP. Nous nous réjouissons à la perspective
des modifications qui seront apportées au programme du RCDP
à compter du 1er juin 2009. Compte tenu de la transition vers
le nouveau système de commande en ligne et du nouveau
partenaire distributeur (Lynden), nous désirons vous informer
que dorénavant :
Nous avons le plaisir de vous annoncer que
vous pouvez maintnant recevoir le Bulletin
• GlaxoSmithKline n’acceptera aucune demande de
remboursement de suppléments sur les ventes en gros ou
d’allocations de distribution sur dans le secteur hospitalier.
Nous vous invitons à prendre connaissance de cet avis télécopié
afin d’adapter vos processus en conséquence.
par courriel ou par télécopieur!
Si vous souhaitez le recevoir par télécopieur
ou par courriel uniquement, veuillez nous en
informer à:
[email protected]
GSK entend continuer à fournir un service à la clientèle hors
pair pour tous ses produits pharmaceutiques. Si vous avez des
questions au sujet du présent avis, veuillez communiquer avec
le Service à la clientèle de GSK au 1-800-387-7374.
SUR LE FIL
• TORONTO: Health Canada has approved Actonel (risedronate sodium tablets) 150 mg, Canada’s first and only once-a-month dosing option
in the treatment of postmenopausal osteoporosis. Canadian patients at high risk of osteoporotic fracture now have the convenience of taking
one tablet on the same day each month.
• QUEBEC: Quebec’s Health and Welfare Commission, after a recent public consultation, found that most people in Quebec wanted
amniocentesis to be available for any woman who wants it, regardless of age. Amniocentesis testing for Down syndrome is usually suggested
and publicly covered only for pregnant women 35 and older. Some of those with Down syndrome, however, say making the test available for
all pregnant women would amount to institutionalized discrimination. Statistics in other countries show that 90 per cent of women end their
pregnancy after a positive test.
• BASEL, SWITZERLAND: Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung
cancer (NSCLC) who received Avastin (bevacizumab) and Tarceva (erlotinib) as combined first-line maintenance treatment had a 39 percent
improvement in the time they lived without the disease advancing (progression-free survival or PFS, the primary endpoint of the study),
compared with those who received Avastin alone. The ATLAS study was stopped early because of the superior efficacy for patients in the
combined treatment group.
• MISSISSAUGA: The Meningitis Research Foundation of Canada
(MRFC) applauds the government of Ontario’s decision to introduce a routine immunization program that will provide broad protection against
all four of the vaccine-preventable strains of invasive meningococcal disease (IMD). Beginning in September, all grade 7 students in Ontario
will be offered a vaccine called Menactra.
• KIRKLAND, QC: A new treatment option is now available in Canada as an adjunct to standard therapy, to reduce the risk of death following a
heart attack in clinically stable patients who have evidence of heart failure and left ventricular systolic dysfunction: INSPRA (eplerenone tablets)
is the first aldosterone receptor blocker to be approved for this indication in Canada. “Pfizer Canada is pleased to introduce INSPRA as part of
our established portfolio of cardiovascular treatment options. This innovative medication will provide Canadians afflicted by congestive heart
failure after a myocardial infarcation, with a proven and effective treatment,” said Dr. Bernard Prigent, Vice President and Medical Director,
Pfizer Canada Inc.
• SEATTLE, WASHINGTON: An anti-depressant that is among the most popular kinds of medicine used for treating autism didn’t work for most
kids and caused nightmares and other side-effects, new research found. Results showed risks with citalopram, sold in Canada and the U.S.
as Celexa, outweighed any benefits in the largest published study of medication versus dummy pills for autism. The drug is not approved for
treating autism. However, many doctors have prescribed it, thinking it might help prevent repetitive behaviours such as spinning, twirling, and
head-banging that are hallmark autism symptoms. Similiar antidepressants have been showen to help treat repetitive actions in people with
obsessive-compulsive disorder.
Veuillez communiquer tout changement concernant le nom de la pharmacie, du pharmacien ou le numéro de télécopieur à : HRC : 416 863-9620 | [email protected]